KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Cash (2018 - 2025)

Castle Biosciences' Change in Cash history spans 7 years, with the latest figure at $31.2 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 25.95% year-over-year to $31.2 million; the TTM value through Dec 2025 reached -$3.0 million, down 114.28%, while the annual FY2025 figure was -$3.0 million, 114.28% down from the prior year.
  • Change in Cash for Q4 2025 was $31.2 million at Castle Biosciences, up from $3.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $31.2 million in Q4 2025 and bottomed at -$139.0 million in Q3 2022.
  • The 5-year median for Change in Cash is -$7.8 million (2023), against an average of -$14.7 million.
  • The largest annual shift saw Change in Cash plummeted 2592.48% in 2022 before it soared 301.83% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$33.5 million in 2021, then surged by 66.52% to -$11.2 million in 2022, then skyrocketed by 167.82% to $7.6 million in 2023, then skyrocketed by 224.89% to $24.8 million in 2024, then rose by 25.95% to $31.2 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Change in Cash are $31.2 million (Q4 2025), $3.3 million (Q3 2025), and -$7.5 million (Q2 2025).